1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2016

Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Hormone Refractory Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Refractory Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Five Countries Contributing to Clinical Trials in Europe 8
Top Countries Contributing to Clinical Trials in North America 9
Top Countries Contributing to Clinical Trials in Middle East and Africa 10
Top Countries Contributing to Clinical Trials in Central and South America 11
Clinical Trials by G7 Countries: Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in E7 Countries 16
Clinical Trials in E7 Countries by Trial Status 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Top Companies Participating in Hormone Refractory Breast Cancer Therapeutics Clinical Trials 24
Prominent Drugs 26
Clinical Trial Profile Snapshots 27
Appendix 38
Abbreviations 38
Definitions 38
Research Methodology 39
Secondary Research 39
About GlobalData 40
Contact Us 40
Disclaimer 40
Source 41

List of Tables
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 5
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 8
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 9
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 10
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 11
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 16
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 17
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 18
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Hormone Refractory Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 22
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 23
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26

List of Figures
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 8
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 9
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 10
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 11
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Hormone Refractory Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Hormone Refractory Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 16
Hormone Refractory Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 17
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19
Hormone Refractory Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Hormone Refractory Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 22
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 23
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 24
Hormone Refractory Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26
GlobalData Methodology 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Oncology Devices - Medical Devices Pipeline Assessment, 2016

Oncology Devices - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Oncology Devices - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Oncology Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of ...

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" ...

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • December 2016
  • by Global Data

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that ...


Download Unlimited Documents from Trusted Public Sources

Cancer and Breast Cancer Statistics in Switzerland

  • February 2017
    138 pages
  • Cancer  

    Breast Cancer  

    Obesity  

  • Switzerland  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • February 2017
    15 pages
  • Cancer  

  • United Kingdom  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.